A review of PSA use in screening for prostate cancer

Screening for prostate cancer using prostate specific antigen (PSA) testing continues to be problematic. Even though it is unproven whether population-wide screening with PSA can reduce death, illness or disability from prostate cancer, testing has become common in North America.

A recent nation-wide survey indicates almost half of Canadian men over 50 years old are tested during their lifetime. In this review, Drs. Ian Thompson and Donna Ankerst examine the evidence in support of the blood test and then discuss how physicians should advise patients about the merits and drawbacks of the test.

In a related commentary, Dr. Michael Jewett and colleagues examine the evidence from two large studies indicating that the drug finasteride is beneficial in reducing both the size of enlarged prostate glands and the risk of prostate cancer.


http://www.cma.ca/cmaj

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer